美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Telix Pharmaceuticals Ltd. (Uplisting)

16.96

+0.16380.98%

盘前：16.50-0.4600-2.71%08:36 EDT

成交量：8,165.00

成交额：13.73万

市值：57.37亿

市盈率：189.53

高：17.10

开：16.87

低：16.55

收：16.80

数据加载中...

总览公司新闻公告

中金三连调该医药股目标价背后：多管线进入临床关键阶段

Synthetix社区提议以2700万美元估值收购去中心化期权平台Derive

中金：维持远大医药“跑赢行业”评级升目标价至9.6港元

远大医药TLX591-CDx国内III期临床给药完成计划今年内递交新药上市申请

中国网财经

重症+核药连获里程碑进展!远大医药获中金上调目标价，全球首个零辐射核药基地投产在即

智通财经网

全球首个零辐射核药研发生产基地蓄势待发，远大医药创新产品管线夯实核药国际领军地位

远大医药：全球创新放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请已获中国药监局受理

异动解读 | Telix Pharmaceuticals公布2024财年业绩大涨,盘中股价暴涨10%

Telix Pharmaceutic2024财年实现净利润32.93百万美元，同比增加851.73%

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/TLX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":16.96,"timestamp":1750276800000,"preClose":16.7962,"halted":0,"volume":8165,"hourTrading":{"tag":"盘前","latestPrice":16.5,"preClose":16.96,"latestTime":"08:36 EDT","volume":2017,"amount":33273.589757999995,"timestamp":1750422971368},"delay":0,"floatShares":275251135,"shares":338248789,"eps":0.089486,"marketStatus":"盘前交易","change":0.1638,"latestTime":"06-20 08:47:15 EDT","open":16.87,"high":17.101,"low":16.5501,"amount":137315.271255,"amplitude":0.032799,"askPrice":16.6,"askSize":200,"bidPrice":16.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1750426200000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":16.96,"preHourTrading":{"tag":"盘前","latestPrice":16.5,"preClose":16.96,"latestTime":"08:36 EDT","volume":2017,"amount":33273.589757999995,"timestamp":1750422971368},"postHourTrading":{"tag":"盘后","latestPrice":16.96,"preClose":16.96,"latestTime":"17:52 EDT","volume":25,"amount":424.2,"timestamp":1750283562051},"volumeRatio":0.33739111582920395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275251135,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":0.33739111582920395,"shares":338248789,"dividePrice":0,"high":17.101,"amplitude":0.032799,"preClose":16.7962,"low":16.5501,"week52Low":13.61,"pbRate":"15.55","psRate":"11.28","week52High":30.36,"institutionHeld":0,"latestPrice":16.96,"committee":-0.333333,"eps":0.089486,"divideRate":0,"volume":8165,"delay":0,"ttmEps":0.089486,"open":16.87,"prevYearClose":15.4,"prevWeekClose":16.09,"prevMonthClose":16.9899,"prevQuarterClose":16.76,"fiveDayClose":17.04,"twentyDayClose":16.4,"sixtyDayClose":18.2377},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535831468","title":"中金三连调该医药股目标价背后：多管线进入临床关键阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2535831468","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535831468?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 09:24","pubTimestamp":1747272240,"startTime":"0","endTime":"0","summary":"远大医药多管线进入临床关键阶段，中金三次上调其目标价。其自研药物STC3141脓毒症II期临床成功，TLX591前列腺癌药国际III期临床获受理，并计划今年递交上市申请。同时，公司另一核药GPN02006也将在国际会议上公布研究成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515094230975a1599&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515094230975a1599&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512","TLX"],"gpt_icon":0},{"id":"2535206284","title":"Synthetix社区提议以2700万美元估值收购去中心化期权平台Derive","url":"https://stock-news.laohu8.com/highlight/detail?id=2535206284","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535206284?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 13:02","pubTimestamp":1747198964,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://blog.synthetix.io/synthetix-derive-set-to-unite-for-mainnet-perpetual-futures/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["03046","CETH","09009","03179","09046","SNX.USD.CC","BK4594","IBIT","BK4585","SNX","BK4588","ETH","ETHW","OP.USD.HKCC","ETHE","BK4601","DRV","ETH.USD.HKCC","03009","BK1611","FETH","LDO.USD.HKCC","EZET","BK4140","SPAQ.U","09179","QETH","SNX.USD.HKCC","BK4139","ETHA","ETH.USD.CC","TLX","ETHV"],"gpt_icon":0},{"id":"2535057709","title":"中金：维持远大医药“跑赢行业”评级 升目标价至9.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535057709","media":"新浪网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535057709?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 10:10","pubTimestamp":1747188629,"startTime":"0","endTime":"0","summary":"中金发布研报称，维持远大医药2025年/2026年EPS预测0.6/0.63港币不变。该行维持“跑赢行业”评级，考虑到公司RDC管线接近收获，上调目标价20.0%至9.6港币，对应2025年/2026年16.0倍/15.2倍市盈率，较当前股价有15.4%的上行空间。5月7日，公司公告创新RDC产品TLX591加入国际多中心III期临床试验的申请已经获得国家药监局受理。在本III期临床研究里，公司拟在超过100例前列腺癌患者中评估TLX591-CDx的有效性和安全性，现已完成全部患者入组给药，公司计划今年内提交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051410390294f63205&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051410390294f63205&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX"],"gpt_icon":0},{"id":"2534273125","title":"远大医药TLX591-CDx国内III期临床给药完成 计划今年内递交新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2534273125","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534273125?lang=zh_cn&edition=fundamental","pubTime":"2025-05-12 20:18","pubTimestamp":1747052280,"startTime":"0","endTime":"0","summary":"当日晚间，远大医药公布又一创新核药研发进展，公司用于诊断前列腺癌的全球创新在研放射性核素偶联药物 TLX591-CDx 中国III期临床试验已完成全部患者入组给药，并计划今年内在中国递交新药上市申请，这已是远大医药近期公布的第三项重大创新研发进展。另一方面，远大医药用于治疗前列腺癌的RDC产品TLX591加入国际多中心III期临床试验的申请早前已获得国家药监局受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051221043897573df7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051221043897573df7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4134","TLX","III","BK4139"],"gpt_icon":0},{"id":"2533279182","title":"重症+核药连获里程碑进展!远大医药获中金上调目标价，全球首个零辐射核药基地投产在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2533279182","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533279182?lang=zh_cn&edition=fundamental","pubTime":"2025-05-08 18:46","pubTimestamp":1746701194,"startTime":"0","endTime":"0","summary":"与5月8日收盘价对比，远大医药股价未来至少存在超过12%的上行空间。脓毒症是因感染引发的免疫反应失调导致的致命性器官功能障碍，死亡率高达25%-60%。TLX591-CDx计划于今年二季度完成中国III期临床的全部患者入组。目前，远大医药在核药抗肿瘤诊疗板块已有4款RDC创新药获批开展注册性临床研究，其中3款已进入III期临床阶段。据悉，远大医药该核药基地预计将投入总计约30亿元，并预计将于今年年底至2026年","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050818572994f06852&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050818572994f06852&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX"],"gpt_icon":0},{"id":"2533183719","title":"全球首个零辐射核药研发生产基地蓄势待发，远大医药创新产品管线夯实核药国际领军地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2533183719","media":"新浪医药","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533183719?lang=zh_cn&edition=fundamental","pubTime":"2025-05-08 08:46","pubTimestamp":1746665181,"startTime":"0","endTime":"0","summary":"远大医药目前是拥有进入中国III期临床研究中诊断和治疗类RDC创新药总计储备最多的企业，也是全球范围内在核药抗肿瘤领域拥有最丰富产品管线和诊疗一体化布局的创新药企之一，是名副其实的全球核药领军企业。值得注意的是，远大医药用于诊断前列腺癌的全球创新RDC产品TLX591-CDx计划于今年二季度完成中国III期临床的全部患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508085210a475fb05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508085210a475fb05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX","RDC","BK4139"],"gpt_icon":0},{"id":"2533984405","title":"远大医药：全球创新放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请已获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984405","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984405?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 19:25","pubTimestamp":1746617119,"startTime":"0","endTime":"0","summary":"格隆汇5月7日丨远大医药公告，集团用于治疗前列腺癌的全球创新放射性核素偶联药物TLX591 加入国际多中心III期临床试验的申请，近日已获得中国国家药品监督管理局正式受理，这是集团在核药抗肿瘤诊疗领域的重要研发进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507192759a4754c2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507192759a4754c2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX","III","BK4134","BK4139"],"gpt_icon":0},{"id":"1195239442","title":"异动解读 | Telix Pharmaceuticals公布2024财年业绩大涨,盘中股价暴涨10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195239442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195239442?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 22:32","pubTimestamp":1740407544,"startTime":"0","endTime":"0","summary":"2025年2月24日,周一盘中,Telix Pharmaceuticals(TLX.US)股价大涨10%,引发市场广泛关注。\n\n此前,Telix公布了2024财年财报,财报显示公司2024财年净利润达到3293万美元,同比大涨851.73%。营业收入也同比增长54.79%至5.17亿美元,利润和收入双双大幅增长。\n\nTelix是一家开发治疗和成像癌症的放射性药物的生物制药公司。其主打产品Illuccix用于前列腺癌成像,在美国已实现大规模商业化销售。财报数据反映了公司业务高速增长的良好态势,有力增强了市场对公司长期发展前景的信心,成为推动股价暴涨的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Telix Pharmaceuticals公布2024财年业绩大涨,盘中股价暴涨10%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TLX"],"gpt_icon":0},{"id":"2513796469","title":"Telix Pharmaceutic2024财年实现净利润32.93百万美元，同比增加851.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513796469","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513796469?lang=zh_cn&edition=fundamental","pubTime":"2025-02-24 11:01","pubTimestamp":1740366068,"startTime":"0","endTime":"0","summary":"2月24日，Telix Pharmaceutic公布财报，公告显示公司2024财年净利润为32.93百万美元，同比增加851.73%；其中营业收入为5.17亿美元，同比增加54.79%，每股基本收益为0.10美元。从资产负债表来看，Telix Pharmaceutic总负债5.92亿美元，其中短期债务13.30百万美元，资产负债比为1.60，流动比率为2.78。机构评级：截至2025年2月24日，当前有5家机构对Telix Pharmaceutic目标价做出预测，其中目标均价为21.96美元，其中最低目标价为21.04美元，最高目标价为22.95美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224110119a25153b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224110119a25153b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TLX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1749182400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-06-18","current":174.480785,"percent":0.44898,"low":151.061716,"twenty":167.889662,"median":176.235021,"eighty":187.353158,"high":205.576265,"avg":177.561072,"sd":12.206046,"marketCap":5680126722.32},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-18","current":174.480785,"twenty":167.889662,"median":176.235021,"eighty":187.353158,"marketCap":5680126722.32}],"updateTime":1750423635474}}}